CD63 and breast carcinoma: Administration of sulfisoxazole (SFX), an FDA approved antibiotic, inhibits the biogenesis of EVs from breast cancer cells and prevents EV secretion via downregulation of the components of the ESCRT-dependent machine, such as CD63, RAB27, and RAB7 (92).